FLORHAM PARK, N.J. - Cellectar Biosciences, Inc. (NASDAQ: NASDAQ:CLRB), a biopharmaceutical company specializing in oncology, has reported positive results from a Phase 1 clinical trial of iopofosine I 131 in combination with external beam radiation therapy (EBRT) for treating recurrent head and neck squamous cell carcinoma.
The trial, supported by a SPORE Grant, showed a complete remission rate of 64% and an overall response rate of 73% in patients with highly refractory disease.
The study included 12 patients who had previously undergone various treatments including chemoradiation, surgery, or a combination of both. The results, presented at the recent Multidisciplinary Head and Neck Cancers Symposium, demonstrated a 67% overall survival rate and a 42% progression-free survival rate at one year.
Iopofosine I 131 was administered at a fixed fractionated dose, followed by EBRT to complete the radiation dose as per the reirradiation plan. According to the company, the combination therapy was well-tolerated, and the adverse events observed were consistent with the known toxicity profile of the drug, primarily cytopenias.
The success of the trial suggests that the combination of iopofosine and EBRT may not only target the primary tumor but could also have a synergistic effect on micrometastatic disease beyond the conventional radiation field. This could potentially apply to a variety of solid tumors.
Cellectar's focus on leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform aims to improve the targeting of cancer treatments, reducing off-target effects and enhancing efficacy.
The company has a product pipeline that includes the lead asset iopofosine I 131, preclinical PDC chemotherapeutic programs, and partnered PDC assets.
This news is based on a press release statement from Cellectar Biosciences, which is currently undertaking research and development collaborations to further its cancer treatment objectives. The company has previously reported favorable data in hematologic malignancies, including results from the pivotal CLOVER WaM study in Waldenstrom’s macroglobulinemia, indicating broad clinical activity of iopofosine in solid tumors as well.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.